Drug Development Research, Год журнала: 2025, Номер 86(3)
Опубликована: Апрель 28, 2025
ABSTRACT Idiopathic pulmonary fibrosis is a progressive, irreversible lung disease of unknown cause, characterized by gradual thickening and scarring tissue, impairing oxygen transfer into the bloodstream. As result, symptoms such as shortness breath, fatigue, persistent dry cough occur. Currently, FDA‐approved antifibrotic agents Pirfenidone Nintedanib can slow progression disease. However, these treatments cannot completely stop loss function do not provide significant improvement in quality life patients. progresses, capacity decreases, breath increases, general health deteriorates significantly. Therefore, new more effective, targeted therapies that halt IPF are urgently needed. This review addresses novel strategies to or disease‐related targeting key mechanisms involved pathogenesis IPF. The molecular structure–activity relationships (SARs) synthesized compounds JAK/STAT, TGF‐β/Smad, Wnt/β‐catenin, PI3K, JNK1, other critical signaling pathways were examined. These approaches have great potential for development potent selective therapeutic treatment insights provided this may contribute future efficient drugs.
Язык: Английский